Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director · CEO | March 16, 2024 | March 26, 2024 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | August 18, 2026 | August 18, 2026 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | November 26, 2019 | November 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date March 16, 2024 · Filed March 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,157,593 |
Reported balance
After 2024-03-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-03-16 · Exercise / conversion · Acquired 84,847 · Balance 1,157,593 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,124,565 |
Reported balance
After 2024-03-21 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-03-21 · Sale · Disposed 33,028 · Balance 1,124,565 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 1,137,065 |
Reported balance
After 2024-03-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2024-03-16 · Exercise / conversion · Acquired 12,500 · Balance 1,137,065 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,133,979 |
Reported balance
After 2024-03-21 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2024-03-21 · Sale · Disposed 3,086 · Balance 1,133,979 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 1,146,954 |
Reported balance
After 2024-03-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2024-03-16 · Exercise / conversion · Acquired 12,975 · Balance 1,146,954 F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 .. |
| Common StockSEC Table I · non-derivative | Direct | 1,143,788 |
Reported balance
After 2024-03-21 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2024-03-21 · Sale · Disposed 3,166 · Balance 1,143,788 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 84,847 |
Reported balance
After 2024-03-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-03-16 · Exercise / conversion · Disposed 84,847 · Balance 84,847 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,500 |
Reported balance
After 2024-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-16 · Exercise / conversion · Disposed 12,500 · Balance 12,500 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-16 · Exercise / conversion · Disposed 12,975 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2024 ..
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
EyePoint, Inc.
Report date August 18, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,100 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 10,600 · Balance 49,100 |
VIVEVE MEDICAL, INC.
Report date November 26, 2019 · Filed November 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2029-11-25 | Direct | 330,000 |
Reported balance
After 2019-11-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-26 · Grant · Acquired 330,000 · Balance 330,000 F1: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2019 Filed May 31, 2019 16:31 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 35,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001437749-19-011166 · rdgdoc.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 35,000 non-qualified stock options on May 29, 2019 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:34 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 14,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-006479 · rdgdoc.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,518 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 14,248 shares of common stock on April 1, 2019 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 18:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 16,015 | $17.57 | $281,383.55 |
DisclosureSEC source: 0001179110-19-002059 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,224 Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 15:48 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 9,524 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-000070 · rdgdoc.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,270 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 9,524 shares of common stock on December 31, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:36 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 17,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-014321 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 27, 2018 Filed Dec 31, 2018 21:36 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 59,700 | $0.00 Strike: $19.17 | $0.00 |
DisclosureSEC source: 0001179110-18-014321 · edgar.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,700 Underlying: Common Stock · 59,700 shares Expires 2028-12-27 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 14:29 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 30,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-18-014217 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 70,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-18-013086 · edgar.xml · derivative · entry 3 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 6,761 | $28.37 | $191,809.57 |
DisclosureSEC source: 0001179110-18-013086 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,209 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 70,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 63,239 shares of common stock. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:26 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 70,000 | $2.74 | $191,800.00 |
DisclosureSEC source: 0001179110-18-013086 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 70,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock swap, the Reporting Person, on a net basis, acquired ownership of an additional 63,239 shares of common stock. Read SEC document |
| November 19, 2018 Filed Dec 21, 2018 14:29 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 30,000 | $2.74 | $82,200.00 |
DisclosureSEC source: 0001179110-18-014217 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 22:14 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 12,000 | $32.93 | $395,160.00 |
DisclosureSEC source: 0001179110-18-012898 · edgar.xml · nonDerivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,970 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.45 to $33.39. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 22:14 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 13,000 | $33.42 | $434,460.00 |
DisclosureSEC source: 0001179110-18-012898 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,970 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.77 to $33.78. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 13:17 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 746 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-017960 · rdgdoc.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 746 shares of common stock on October 1, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 14:08 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Options · Derivative | 70,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001437749-18-017039 · rdgdoc.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-09-12 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 70,000 incentive stock options on September 13, 2018 (the "Grant Date"). The non-qualified stock options will vest in equal annual installments over three years beginning on the first anniversary of the Grant Date. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 20:44 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 10,060 | $39.30 | $395,358.00 |
DisclosureSEC source: 0001179110-18-010453 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,970 F1 · shares: This Form is being filed to report the delivery of shares of Common Stock of the Company for payment of tax liabilities that resulted from the exercise of a stock option reported on Form 4 for the reporting person filed on August 6, 2018. The fair market value of the Company's Common Stock on the date of exercise of such stock option was $39.25, and the amount of shares transferred to the Company on August 7, 2018 was based on the tax liability that accrued on the date of the exercise on August 2, 2018. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:00 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 175,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001179110-18-010330 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 175,000 shares Expires 2018-12-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2018 Filed Aug 6, 2018 22:00 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 175,000 | $2.74 | $479,500.00 |
DisclosureSEC source: 0001179110-18-010330 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:52 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015737 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock. F3 · derivative.exercise_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 18, 2021 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 23:52 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 75,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015737 · edgar.xml · derivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 18, 2021 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 18, 2019 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 22:23 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 209,500 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000101 · edgar.xml · derivative · entry 2 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,500 Underlying: Common Stock · 209,500 shares Expires 2026-12-29 F2 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option will be fully vested on December 29, 2020 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on December 29, 2017 (12 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 22:23 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000101 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,147 F1 · shares: Represents shares underlying retention-based restricted stock units, all of which shall become vested on January 1, 2020 so long as the reporting person's employment is continuous from December 29, 2016 through January 1, 2020. Read SEC document |
| October 07, 2016 Filed Oct 14, 2016 17:37 UTC | Axogen, Inc. AXGN · Entity 4297 | PurchaseCommon Stock | 10,000 | $7.50 | $75,000.00 |
DisclosureSEC source: 0001179110-16-030705 · edgar.xml · nonDerivative · entry 1 Zaderej Karen L. · CIK 0001530968 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,147 F1 · shares: The reporting person purchased these shares in her individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. F1 · price: The reporting person purchased these shares in her individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On October 7, 2016, the trade date for the public offering, the closing sale price reported by NASDAQ was $9.15 per share. The public offering closed on October 13, 2016 and the closing sale price reported by NASDAQ on such date was $8.72 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.